BTdCPU
Based on 3 publication(s) in Google Scholar
BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma.
For research use only. We do not sell to patients.
- Purity: 99.03%
- CAS No.: 1257423-87-2
- Formula: C13H8Cl2N4OS
- Molecular Weight:339.20
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) BTdCPU
More
Biological Activity
BTdCPU (10 μM; 4, 8 h) BTdCPU induces phosphorylation of eIF2α and promotes cell death in MM cells[1].
BTdCPU (10 μM; 4, 8 h) shows cytotoxic for dex-resistant primary MM cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MM1.S and MM1.R cells
-
Concentration:10 μM
-
Incubation Time:0, 4, 8 h
-
Result:Induced phosphorylation of eIF2α and upregulated mRNA and protein levels of the pro-apoptotic protein CHOP.
-
Cell Line:Bone marrow mononuclear cells (MNC) from multiple myeloma (MM) patient or healthy donor
-
Concentration:10 μM
-
Incubation Time:0, 4, 8 h
-
Result:Induced early expression of CHOP in MM patient cells, but not in healthy bone marrow mononuclear cells (MNC).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female nude mice (mice xenograft breast tumors model)[2].
-
Dosage:175 mg/kg
-
Administration:Intraperitoneal injection; single daily for 21 days
-
Result:Led to complete tumor stasis,which persisted for the remainder of the 3-week study
Showed good safety in mice.
Chemical Information
-
CAS No. 1257423-87-2
-
Appearance Solid
-
Molecular Weight 339.20
-
Formula C13H8Cl2N4OS
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C2N=NSC2=C1)NC3=CC=C(C(Cl)=C3)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
Pharmacological targeting of RIG-I can selectively activate the integrated stress response. [Abstract]2025 Oct 31;11(44):eadt3014. PMID: 41160678 -
PLoS Negl Trop Dis
Relevance of oxidative stress in inhibition of eIF2 alpha phosphorylation and stress granules formation during Usutu virus infection. [Abstract]2021 Jan 25;15(1):e0009072. PMID: 33493202 -
Solvent & Solubility
DMSO : 125 mg/mL (368.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (6.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Burwick N, et al. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 Apr;55:23-32. [Content Brief]
[2]. Chen T, et al. Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol. 2011 Jul 17;7(9):610-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9481 mL | 14.7406 mL | 29.4811 mL | 73.7028 mL |
| 5 mM | 0.5896 mL | 2.9481 mL | 5.8962 mL | 14.7406 mL | |
| 10 mM | 0.2948 mL | 1.4741 mL | 2.9481 mL | 7.3703 mL | |
| 15 mM | 0.1965 mL | 0.9827 mL | 1.9654 mL | 4.9135 mL | |
| 20 mM | 0.1474 mL | 0.7370 mL | 1.4741 mL | 3.6851 mL | |
| 25 mM | 0.1179 mL | 0.5896 mL | 1.1792 mL | 2.9481 mL | |
| 30 mM | 0.0983 mL | 0.4914 mL | 0.9827 mL | 2.4568 mL | |
| 40 mM | 0.0737 mL | 0.3685 mL | 0.7370 mL | 1.8426 mL | |
| 50 mM | 0.0590 mL | 0.2948 mL | 0.5896 mL | 1.4741 mL | |
| 60 mM | 0.0491 mL | 0.2457 mL | 0.4914 mL | 1.2284 mL | |
| 80 mM | 0.0369 mL | 0.1843 mL | 0.3685 mL | 0.9213 mL | |
| 100 mM | 0.0295 mL | 0.1474 mL | 0.2948 mL | 0.7370 mL |